Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIV001 in mild-to-moderate active ulcerative colitis
NCT06749795Phase 1Not yet recruiting
- Sponsor
- Liveome
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing LIV001 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events (AEs) at 12 weeks, Number of subjects with clinical laboratory abnormalities at 12 weeks and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
LIV001
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06749795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749795.